DB17954InvestigationalCell transplant therapies
NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS),...
- Code names
- NSI-566
Resolves to
Compound
What you can answer from here — as of April 02, 2025
Which companies are running trials of NSI-566, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account